326 related articles for article (PubMed ID: 31492588)
21. The activity of the carbamoyl phosphate synthase 1 promoter in human liver-derived cells is dependent on hepatocyte nuclear factor 3-beta.
Chen Z; Tang N; Wang X; Chen Y
J Cell Mol Med; 2017 Sep; 21(9):2036-2045. PubMed ID: 28272778
[TBL] [Abstract][Full Text] [Related]
22. Y-box binding protein-1 down-regulates expression of carbamoyl phosphate synthetase-I by suppressing CCAAT enhancer-binding protein-alpha function in mice.
Chen YR; Sekine K; Nakamura K; Yanai H; Tanaka M; Miyajima A
Gastroenterology; 2009 Jul; 137(1):330-40. PubMed ID: 19272383
[TBL] [Abstract][Full Text] [Related]
23. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
[TBL] [Abstract][Full Text] [Related]
24. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
25. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
Lehrer S; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
Guan Y; He Y; Lv S; Hou X; Li L; Song J
J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
[TBL] [Abstract][Full Text] [Related]
27. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.
Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.
Wu T; Luo G; Lian Q; Sui C; Tang J; Zhu Y; Zheng B; Li Z; Zhang Y; Zhang Y; Bao J; Hu J; Shen S; Yang Z; Wu J; Wang K; Zhao Y; Yang S; Wang S; Qiu X; Wang W; Wu X; Wang H; Gu J; Chen L
Hepatology; 2021 Dec; 74(6):3249-3268. PubMed ID: 34343359
[TBL] [Abstract][Full Text] [Related]
30. Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Proteome Association Analysis.
Wang J; Yan S; Chen X; Wang A; Han Z; Liu B; Shen H
Technol Cancer Res Treat; 2022; 21():15330338211035270. PubMed ID: 35538679
[TBL] [Abstract][Full Text] [Related]
31. NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.
Guo Q; Han N; Shi L; Yang L; Zhang X; Zhou Y; Yu S; Zhang M
Oncol Rep; 2019 Sep; 42(3):963-972. PubMed ID: 31322259
[TBL] [Abstract][Full Text] [Related]
32. Conditional disruption of hepatic carbamoyl phosphate synthetase 1 in mice results in hyperammonemia without orotic aciduria and can be corrected by liver-directed gene therapy.
Khoja S; Nitzahn M; Hermann K; Truong B; Borzone R; Willis B; Rudd M; Palmer DJ; Ng P; Brunetti-Pierri N; Lipshutz GS
Mol Genet Metab; 2018 Aug; 124(4):243-253. PubMed ID: 29801986
[TBL] [Abstract][Full Text] [Related]
33. In search of druggable targets for GBM amino acid metabolism.
Panosyan EH; Lin HJ; Koster J; Lasky JL
BMC Cancer; 2017 Feb; 17(1):162. PubMed ID: 28245795
[TBL] [Abstract][Full Text] [Related]
34. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
[TBL] [Abstract][Full Text] [Related]
35. SLC12A5 as a novel potential biomarker of glioblastoma multiforme.
Chen J; Wang H; Deng C; Fei M
Mol Biol Rep; 2023 May; 50(5):4285-4299. PubMed ID: 36917367
[TBL] [Abstract][Full Text] [Related]
36. Establishment and External Validation of a Hypoxia-Derived Gene Signature for Robustly Predicting Prognosis and Therapeutic Responses in Glioblastoma Multiforme.
Wang K; Lu Y; Liu Z; Diao M; Yang L
Biomed Res Int; 2022; 2022():7858477. PubMed ID: 35155681
[TBL] [Abstract][Full Text] [Related]
37. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
38. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
[TBL] [Abstract][Full Text] [Related]
39. TRAF6 correlated to invasion and poor prognosis of glioblastoma via elevating MMP9 expression.
Sun J; Zhao B; Du K; Liu P
Neuroreport; 2019 Jan; 30(2):127-133. PubMed ID: 30571666
[TBL] [Abstract][Full Text] [Related]
40. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
